# Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma

Source: https://onco.cc/trials/nct07102901/  
OnCo record `nct07102901` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Trastuzumab rezetecan and Retlirafusp alfa in gastric & gastro-oesophageal junction cancer, run by Jiangsu HengRui Medicine Co., Ltd., now recruiting.

## Summary

Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma is a phase 2 interventional study registered as NCT07102901 by Jiangsu HengRui Medicine Co., Ltd., with 351 participants planned, started 2025-09-05 and due to reach its primary completion in 2027-12. Interventions recorded: SHR2554 Tablets, SHR-A1811 Injection, SHR-A1904 Injection and SHR-1701 Injection.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07102901
- Phase: 2
- Setting: A Multicenter, Open-Label Phase II Clinical Study Evaluating the Safety, Tolerability and Efficacy of SHR2554 Tablets in Combination With Other Antitumor Therapies in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastro-oesophageal Junction Adenocarcinoma
- Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- Enrolled: 351

## Sources

- ClinicalTrials.gov NCT07102901: https://clinicaltrials.gov/study/NCT07102901

## Connected records

- cancers: [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/)
- drugs: [Retlirafusp alfa](https://onco.cc/drugs/retlirafusp-alfa/), [Trastuzumab rezetecan](https://onco.cc/drugs/trastuzumab-rezetecan/)
- companies: [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/)

---
JSON: https://onco.cc/api/v1/entities/nct07102901.json